Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib

A 63-year-old woman with pulmonary adenocarcinoma (stage IIIB) that was positive for an epidermal growth factor receptor (EGFR) mutation and an anaplastic lymphoma kinase (ALK) rearrangement was treated with erlotinib as the first-line treatment, resulting in a stable disease. Due to skin rashes, fa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Intern Med
Main Authors: Yokoyama, Akira, Tamura, Atsuhisa, Miyakawa, Kazuko, Kusaka, Kei, Shimada, Masahiro, Hirose, Takashi, Matsui, Hirotoshi, Kitani, Masashi, Hebisawa, Akira, Ohta, Ken
Formato: Artigo
Idioma:Inglês
Publicado em: The Japanese Society of Internal Medicine 2018
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6148164/
https://ncbi.nlm.nih.gov/pubmed/29526950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.0383-17
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados